Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Cost of Revenue: 2021-2025

Historic Cost of Revenue for Rhythm Pharmaceuticals (RYTM) over the last 5 years, with Sep 2025 value amounting to $5.5 million.

  • Rhythm Pharmaceuticals' Cost of Revenue rose 43.65% to $5.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.5 million, marking a year-over-year increase of 44.18%. This contributed to the annual value of $13.4 million for FY2024, which is 43.71% up from last year.
  • According to the latest figures from Q3 2025, Rhythm Pharmaceuticals' Cost of Revenue is $5.5 million, which was down 0.79% from $5.5 million recorded in Q2 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' Cost of Revenue peaked at $5.5 million during Q2 2025, and registered a low of $4,000 during Q1 2021.
  • For the 3-year period, Rhythm Pharmaceuticals' Cost of Revenue averaged around $3.4 million, with its median value being $3.2 million (2023).
  • Data for Rhythm Pharmaceuticals' Cost of Revenue shows a peak YoY spiked of 5,650.00% (in 2022) over the last 5 years.
  • Quarterly analysis of 5 years shows Rhythm Pharmaceuticals' Cost of Revenue stood at $236,000 in 2021, then surged by 335.59% to $1.0 million in 2022, then soared by 214.49% to $3.2 million in 2023, then climbed by 17.14% to $3.8 million in 2024, then soared by 43.65% to $5.5 million in 2025.
  • Its Cost of Revenue was $5.5 million in Q3 2025, compared to $5.5 million in Q2 2025 and $3.6 million in Q1 2025.